​What is the dosage of Selpercatinib?

Selpercatinib is a targeted drug that specifically targets mutations in the RET gene. By inhibiting RET kinase activity, it prevents the growth and spread of cancer cells. It is suitable for the treatment of diseases such as non-small cell lung cancer and medullary thyroid cancer.

What is the dosage of Selpercatinib?

Before using Selpercatinib, it is important to follow your doctor's specific instructions and recommendations to understand the dosage of the drug.

1. Renal impairment

For patients with severe renal impairment (eGFR estimated by MDRD of 15 to 29 mL/min/1.73 m²), the recommended dose of Selpercatinib is 9 mg and the dosing schedule (intermittent or continuous) for the indication is specified.

2. Liver damage

For patients with severe hepatic impairment (total bilirubin more than 3 times ULN with any elevated AST level), the recommended dose of Selpercatinib is 9 mg and the dosing schedule (intermittent or continuous) for the indication is specified.

What are the indications for Selpercatinib?

Selpercatinib is indicated for the following specific types of cancer, please learn about the specific indications.

1. RET-mutant medullary thyroid cancer (MTC)

For adult and pediatric patients 2 years of age and older who have been confirmed by an FDA-approved test to have a RET mutation and have advanced or metastatic medullary thyroid cancer requiring systemic therapy.

2. RET fusion-positive thyroid cancer

Indicated for adult and pediatric patients 2 years of age and older who have advanced or metastatic thyroid cancer requiring systemic therapy and refractory to radioactive iodine therapy with confirmed RET gene fusions by an FDA-approved test.

What are the precautions for selpatinib?

During treatment with Selpercatinib, please note the following important points.

1. Hypothyroidism

Thyroid function should be monitored before and during treatment. Thyroid hormone replacement therapy may be considered depending on clinical need. For more severe cases of hypothyroidism, the drug may need to be stopped temporarily or permanently.

2. Embryo-fetal toxicity

Animal studies have shown that Selpercatinib may be harmful to the fetus. Pregnant women should be counseled about the potential risks, and women of childbearing potential should be advised to use effective contraception during treatment and for a week after the last dose. The same contraception should be used if the male partner is a woman of childbearing potential.

[Warm tips] During the treatment with Selpercatinib, maintain close communication with the doctor, report any discomfort in time, and ensure the smooth progress of the treatment.